Glanbia’s Prolibra weight loss ingredient backed by US patent

By Lorraine Heller

- Last updated on GMT

Related tags: Weight loss, Nutrition

Irish firm Glanbia Nutritionals has received a US patent for its whey-derived weight loss ingredient Prolibra.

Prolibra is a partially hydrolyzed whey protein isolate, high in protein and low in fat and Glanbia's suggested uses for the ingredient include beverages, powdered beverage mixes and snack bars.

Glanbia says that by helping to retain lean muscle mass, Prolibra could ward off the negative effects of the yo-yo dieting that often occurs with traditional diets.

“With overweight and obesity rates still a major concern in the developed world, weight management products can provide a key way to optimize a healthy diet,”​ said Sharon Rokosh, business development manager at Glanbia, adding that the patent reinforces the ingredient’s significance in the weight loss market.

Clinical backing

Since 2004, Glanbia has released the results of numerous studies supporting the weight loss benefits of Prolibra.

These demonstrate that the ingredient can help decrease fat mass while maintaining lean body mass in combination with a hypocaloric diet.

One trial found that Prolibra reduced body fat by almost 6 per cent (with 79 per cent of the weight loss being fat) compared to just over 2 per cent in the control group (where 51 per cent of the weight loss was fat).

Prolibra is also said to help reduce post-prandial glycemic response, which contributes to achieving healthy weight loss, said the firm.

The Glycemic Index is considered to be one dietary approach to weight management. It measures how quickly certain foods release carbohydrates into the body, which then raise consumers' blood glucose levels. High GI foods cause blood sugar levels to rise more rapidly. Low GI foods are thought to provide more sustained energy levels, thereby promoting feelings of satiety.

Participants in a trial testing glycemic response saw a reduction of almost 38 per cent in glyceminc index units after consuming a glucose drink containing the ingredient.

The firm first applied for global patent coverage for its ingredient in 2003, a year before it introduced Prolibra to the US industry.

The awarded patent – 7,790,670 – applies only to the US, and Glanbia continues to wait for its European patent.

Related news

Show more

Related products

show more

Accelerate your supply chain as pressures intensify

Accelerate your supply chain as pressures intensify

William Reed | 10-Sep-2018 | Technical / White Paper

Food, Drink and Non-Food manufacturers are under pressure. Range reviews, massive retail mergers, the backlash against plastic packaging and the ongoing...

Protecting Protein, Protecting the Industry

Protecting Protein, Protecting the Industry

European Specialist Sports Nutrition Alliance | 17-Jul-2018 | Technical / White Paper

Protein spiking, or adulteration, is an emerging issue in Europe. ESSNA knows that as a result of some uncertainty around the regulatory definition of...

ESSNA’s ABC’s of Sports Nutrition

ESSNA’s ABC’s of Sports Nutrition

European Specialist Sports Nutrition Alliance | 13-Jun-2018 | Technical / White Paper

To combat the raft of misconceptions around the sports nutrition world, ESSNA has produced its ultimate guide to the industry, covering everything from...

Innovate in Joint Health with b-2Cool®

Innovate in Joint Health with b-2Cool®

BIOIBERICA, S.A. | 11-Jun-2018 | Data Sheet

b-2Cool® is a natural ingredient supplying native (undenatured) type II collagen.

b-2Cool® is manufactured through a strictly controlled...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars